GlassScriptPhysician profile
Kimberly Vincent
NPI 1548339369
$1,533,775.78
in general payments reported to CMS, 2019-2025
34 companies · $368K in 2025
The $368K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305K · 2020: $82K · 2021: $75K · 2022: $188K · 2023: $226K · 2024: $289K · 2025: $368K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $717K · Travel and Lodging: $130K · Food and Beverage: $27K · Consulting Fee: $7,853 · Education: $255 · Honoraria: $8.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $717,230.77 |
| Travel and Lodging | $129,879.73 |
| Food and Beverage | $27,353.05 |
| Consulting Fee | $7,852.50 |
| Education | $255.48 |
| Honoraria | $8.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $458,930.96 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $238,903.17 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Abbvie INC. | $203,678.30 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $119,748.02 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $103,714.70 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $90,849.76 | 2019-2025 | |
| Amgen INC. | $81,317.43 | 2019-2025 | Otezla, Otezla, Amjevita |
| Galderma Laboratories, L.P. | $73,545.27 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $68,060.47 | 2019-2025 | Cosentyx |
| Genzyme Corporation | $51,481.58 | 2019-2025 | |
| Celgene Corporation | $21,305.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $9,997.57 | 2021-2025 | Sotyktu |
| Epi Health, LLC | $7,228.82 | 2019 | |
| Sun Pharmaceutical Industries INC. | $1,019.98 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Leo Pharma INC. | $744.49 | 2020-2025 | Adbry, Anzupgo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $607.11 | 2019-2024 | Tremfya |
| Aclaris Therapeutics, INC. | $500.00 | 2019 | |
| Janssen Biotech, INC. | $495.56 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $348.62 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $319.89 | 2021-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $165.49 | 2020-2025 | |
| Dermavant Sciences, INC. | $157.55 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $149.21 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.62 | 2023-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $87.99 | 2019-2022 | |
| Journey Medical Corporation | $69.17 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $55.37 | 2021 | |
| Almirall LLC | $45.53 | 2019-2025 | Seysara |
| Kyowa Kirin, INC. | $23.50 | 2024 | Poteligeo |
| Mallinckrodt Hospital Products INC. | $22.87 | 2025 | Acthar |
| Dermira, INC. | $22.49 | 2019 | |
| Biofrontera INC. | $18.41 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.73 | 2019 | |
| Nabriva Therapeutics, Plc | $16.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.